



*For immediate release:*

## So Many Sites in KMR Group's Site Scorecard

CHICAGO, Illinois, September 21, 2016 – KMR Group has just completed its latest upload of current site performance data into the Site Scorecard online application reaching a new milestone of over 200,000 site instances. Representing site performance in all diseases at sites across the globe, the new site performance data will help biopharmaceutical companies and CROs select top-performing sites, ultimately helping reduce the cost and time of clinical trials.

As the only performance based site selection platform, Site Scorecard provides companies with aggregated details on a given site's clinical trial performance directly from major biopharma companies. Site Scorecard's over 200,000 site instances consist of global site performance information at nearly 50,000 distinct sites in all regions and all indications.

Companies spend a lot of time trying to figure out which sites can deliver patients and at what rate, the Site Scorecard tool takes a lot of assumptions out of that equation. The application provides clarity around expectations for a given sites recruitment potential by using a fact-based, performance based approach. Companies can identify the top performing sites based on a variety of factors, including volume of subjects randomized, the speed of actual recruitment or drop-out rate to name just a few. The data can be used for purposes of planning and forecasting, and it can also be used to dialogue with the site to ensure expectations are on target.

In addition to the increase in volume of performance data, KMR Group continues to further refine Site Scorecard. A recent example being enhancements around disease specificity in its Oncology, Neurology, Pain and Psychiatric therapy areas. The company credits its team of analysts and an internal site coding application which permits the careful aggregation of performance data across companies. "Site Scorecard contains the industry's only source for vetted site performance data on interventional clinical trials. Reaching this site performance milestone demonstrates not only the breadth of the application but also the value of using performance data in the site selection process," comments Linda Martin, President and Founder of KMR Group.

### **For more information about KMR Group's Site Scorecard or other clinical tools contact:**

Lyndsey McKay, Marketing and Communications Manager      Tel: +1 (312) 795-0400  
Email: [lmckay \[at\] kmrgroup.com](mailto:lmckay@kmrgroup.com)

### **About KMR**

KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group is an industry leader in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to our propriety and rich datasets. KMR's clinical platform contains the most reliable source for



trial performance, recruitment and site metrics data, with over 25,000 global clinical trials. Clients depend on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites. For more information or for a demonstration of any of KMR's tools, please contact us.

Visit our website at <https://kmrgroup.com>

Follow us on Twitter [@KMRGroupInc](https://twitter.com/KMRGroupInc)

KMR Group  
150 North Wacker Drive, Suite 1070 • Chicago, Illinois 60606 USA  
+1 312-795-0400 • Fax +1 312-795-0491  
Copyright © KMR Group 2016 All rights reserved.